Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results , with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35 billion, close to ...

Discover why Dr. Reddy’s Laboratories remains a strong buy amid robust revenue growth, underappreciated pipeline potential, ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

With fiscal 2025 being a low base year due to losses, earnings per share are forecast to more than double by financial year ...

AbbVie just delivered a financial flex with a $13.3 billion quarter, blowing past expectations—its adjusted earnings per ...

Sirius Therapeutics Inc. raised nearly $50 million in a series B2 financing round May 9 to support its pipeline of small interfering RNA (siRNA) molecules for cardiovascular disease indications.

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) million for the same period in the prior year. The increase of $59 million ...

ProBioGen has partnered with Polpharma Biologics to conduct high-performance cell line development services for a biosimilar ...

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and ...